Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial
Open accessThe DOI matches its Crossref record; 67 of the 71 references it cites were found in a registry or an index.
Abstract
Introduction: Obesity and smoking are the two leading causes of preventable death in the USA. Unfortunately, most smokers gain weight after quitting. Postcessation weight gain (PCWG) is frequently cited as one of the primary barriers to a quit attempt and a common cause of relapse. Further, excessive PCWG may contribute to the onset or progression of metabolic conditions, such as hyperglycaemia and obesity. The efficacy of the current treatments for smoking cessation is modest, and these treatments have no clinically meaningful impact on mitigating PCWG. Here, we outline a novel approach using glucagon-like peptide 1 receptor agonists (GLP-1RA), which have demonstrated efficacy in reducing both food and nicotine intake. This report describes the design of a double-blind, placebo-controlled, randomised clinical trial that evaluates the effects of the GLP-1RA exenatide as an adjunct to nicotine patches on smoking abstinence and PCWG. Methods and analysis: The study will be conducted at two university-affiliated research sites in Houston, Texas, the UTHealth Center for Neurobehavioral Research on Addiction and Baylor College of Medicine Michael E. DeBakey VA Medical Centre. The sample will consist of 216 treatment-seeking smokers with pre-diabetes (haemoglobin A1c of 5.7%–6.4%) and/or overweight (body mass index of 25 kg/m 2 or above). Participants will be randomised (1:1) to receive subcutaneous injections of placebo or 2 mg exenatide, once weekly for 14 weeks. All participants will receive transdermal nicotine replacement therapy and brief smoking cessation counselling for 14 weeks. The primary outcomes are 4-week continuous abstinence and changes in body weight at the end of treatment. The secondary outcomes are (1) abstinence and changes in body weight at 12 weeks post end of treatment and (2) changes in neuroaffective responses to cigarette-related and food-related cues as measured by electroencephalogram. Ethics and dissemination: The study has been approved by the UTHealth Committee for the Protection of Human Subjects (HSC-MS-21-0639) and Baylor College of Medicine Institutional Review Board (H-50543). All participants will sign informed consent. The study results will be disseminated via peer-reviewed publications and conference presentations. Trial registration number: NCT05610800.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Varying results have been reported for the role of GLP-1 and GLP-1 receptor agonists in inducing or maintaining abstinence from nicotine use (appendix pp 16-17), but the GLP-1 receptor agonist exenatide (given once weekly) increased abstinence by 70%.109”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the GLP-1 receptor agonist exenatide (given once weekly) increased abstinence by 70%.109”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [109]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and validation of brief measures of positive and negative affect: The PANAS scales.
Watson, D., Clark, L. A., & Tellegen, A. (1988) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.54.6.1063 · Cited by 32,433
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
(1998) · PubMed · Cited by 10,216
brms : An R Package for Bayesian Multilevel Models Using Stan
Bürkner, P.-C. (2017) · Journal of Statistical Software · doi:10.18637/jss.v080.i01 · Cited by 9,476
The PHQ-8 as a measure of current depression in the general population
Kroenke, K., Strine, T. W., Spitzer, R. L., Williams, J. B. W., Berry, J. T., & Mokdad, A. H. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.06.026 · Cited by 5,121
Cuthbert, B. N., Schupp, H. T., Bradley, M. M., Birbaumer, N., & Lang, P. J. (2000) · Biological Psychology · doi:10.1016/s0301-0511(99)00044-7 · Cited by 1,900
Development of the World Health Organization Global Physical Activity Questionnaire (GPAQ)
Armstrong, T., & Bull, F. (2006) · Journal of Public Health · doi:10.1007/s10389-006-0024-x · Cited by 1,727
Hewson, P. (2015) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2014.12096_1.x · Cited by 1,367
How to get statistically significant effects in any ERP experiment (and why you shouldn't)
Luck, S. J., & Gaspelin, N. (2017) · Psychophysiology · doi:10.1111/psyp.12639 · Cited by 1,195 · cited 1×
“…(ie, pleasant, unpleasant, neutral, food and cigarette related) and, in line with previously published reports 57 58 and methodological recommendations, 59 the amplitude of the late positive potential (LPP) between 400 and 800 ms over a priori selected central and parietal sites will be computed.”
Result
Research works printed but not linked: 5
- 10.1080/14622200125675 · doi:10.1080/14622200125675 · Paper page
- 10.1037/0022-006X.69.5.858 · doi:10.1037/0022-006x.69.5.858 · Paper page
- 10.1037/1064-1297.7.4.354 · doi:10.1037/1064-1297.7.4.354 · Paper page
- 10.1080/14622200124218 · doi:10.1080/14622200124218 · Paper page
- 2015, Boca Raton, J R Stat Soc Ser A Stat Soc, 178
Cited by
Wang, L., Berger, N. A., Kaelber, D. C., & Xu, R. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.04.029 · Cited by 130
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02498-5 · Cited by 83
“To gain access to the data, a request can be made to TriNetX (join@trinetx.com), but costs might be incurred, and a data-sharing agreement would be necessary.”
BackgroundMartinelli, S., Mazzotta, A. D., Longaroni, M., & Petrucciani, N. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.112424 · Cited by 70
Wang, L., Wang, Q., Li, L., Kaelber, D. C., & Xu, R. (2025) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djae260 · Cited by 53
Metadata
- Authors
- Yammine, L., Verrico, C. D., Versace, F., Webber, H. E., Suchting, R., Weaver, M. F., Kosten, T. R., Alibhai, H., Cinciripini, P. M., Lane, S. D., & Schmitz, J. M.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Michael E. DeBakey VA Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Houston (US)
- Corresponding author
- Yammine, Luba
- ORCID
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2023-06
- Volume
- 13
- Issue
- 6
- Pages
- e072707
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC10277057
- OpenAlex
- W4380685040
- Cited by
- 13
- References
- 71
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 6
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (acceptedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health, National Institute of Drug Abuse (1R01DA053241-01A1)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- exenatide, smoking cessation, nicotine patch, nicotine replacement therapy, GLP-1 receptor agonists, prediabetes, overweight, smoking abstinence, food cues, EEG, relapse
- MeSH terms
- Smokers, Exenatide, Humans, Nicotine, Obesity, Prediabetic State, Weight Gain, Randomized Controlled Trials as Topic, Smoking Cessation, Overweight, Tobacco Use Cessation Devices
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial. https://app.cochat.ai/papers/10.1136/bmjopen-2023-072707
- The paper
- Yammine, L., Verrico, C. D., Versace, F., Webber, H. E., Suchting, R., Weaver, M. F., Kosten, T. R., Alibhai, H., Cinciripini, P. M., Lane, S. D., & Schmitz, J. M. (2023). Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial. BMJ Open. https://doi.org/10.1136/bmjopen-2023-072707
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.